Gustavo Rodrigues Rossi

Gustavo Rodrigues Rossi

Auto-generated profile, based on publicly available information

Gustavo Rodrigues Rossi

University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
GRGustavo Rodrigues Rossi
Gustavo Rodrigues Rossi
ETEdvaldo S. Trindade
Edvaldo S. Trindade
Fernando Souza-Fonseca-GuimaraesFernando Souza-Fonseca-Guimaraes
Fernando Souza-Fonseca-Guimaraes
The tumor microenvironment (TME) is composed of multiple infiltrating host cells (e.g., endothelial cells, fibroblasts, lymphocytes, and myeloid cells), extracellular matrix, and various secreted or cell membrane-presented molecules. Group 1 innate lymphoid cells (ILCs), which includes natural killer (NK) cells and ILC1, contribute to protecting the host against cancer and infection. Both subsets are able to quickly produce cytokines such as interferon gamma (IFN-γ), chemokines, and other growth factors in response to activating signals. However, the TME provides many molecules that can prevent the potential effector function of these cells, thereby protecting the tumor. For example, TME-derived tumor growth factor (TGF)-β and associated members of the superfamily downregulate NK cell cytotoxicity, cytokine secretion, metabolism, proliferation, and induce effector NK cells to upregulate ILC1-like characteristics. In concert, a family of carbohydrate-binding proteins called galectins, which can be produced by different cells composing the TME, can downregulate NK cell function. Matrix metalloproteinase (MMP) and a disintegrin and metalloproteinase (ADAM) are also enzymes that can remodel the extracellular matrix and shred receptors from the tumor cell surface, impairing the activation of NK cells and leading to less effective effector functions. Gaining a better understanding of the characteristics of the TME and its associated factors, such as infiltrating cells and extracellular matrix, could lead to tailoring of new personalized immunotherapy approaches. This review provides an overview of our current knowledge on the impact of the TME and extracellular matrix-associated components on differentiation, impairment, and function of NK cells.

21 October 2021 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
AKArutha Kulasinghe
Arutha Kulasinghe
CTChin Wee Tan
Chin Wee Tan
AMAnna Flavia Ribeiro dos Santos Miggiolaro
Anna Flavia Ribeiro dos Santos Miggiolaro
JMJames Monkman
James Monkman
HSHabib SadeghiRad
Habib SadeghiRad
Kenneth O'ByrneKenneth O'Byrne
Kenneth O'Byrne
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which emerged in late 2019 has spread globally, causing a pandemic of respiratory illness designated coronavirus disease 2019 (COVID-19). A better definition of the pulmonary host response to SARS-CoV-2 infection is required to understand viral pathogenesis and to validate putative COVID-19 biomarkers that have been proposed in clinical studies.Methods: Here, we use targeted transcriptomics of formalin-fixed paraffin-embedded tissue using the NanoString GeoMX platform to generate an in-depth picture of the pulmonary transcriptional landscape of COVID-19, pandemic H1N1 influenza and uninfected control patients.Results: Host transcriptomics showed a significant upregulation of genes associated with inflammation, type I interferon production, coagulation and angiogenesis in the lungs of COVID-19 patients compared to non-infected controls. SARS-CoV-2 was non-uniformly distributed in lungs (emphasising the advantages of spatial transcriptomics) with the areas of high viral load associated with an increased type I interferon response. Once the dominant cell type present in the sample, within patient correlations and patient–patient variation, had been controlled for, only a very limited number of genes were differentially expressed between the lungs of fatal influenza and COVID-19 patients. Strikingly, the interferon-associated geneIFI27, previously identified as a useful blood biomarker to differentiate bacterial and viral lung infections, was significantly upregulated in the lungs of COVID-19 patients compared to patients with influenza.Conclusion: Collectively, these data demonstrate that spatial transcriptomics is a powerful tool to identify novel gene signatures within tissues, offering new insights into the pathogenesis of SARS-COV-2 to aid in patient triage and treatment.

27 June 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
Fernando Souza-Fonseca-GuimaraesFernando Souza-Fonseca-Guimaraes
Fernando Souza-Fonseca-Guimaraes
GRGustavo R. Rossi
Gustavo R. Rossi
LDLaura Francesca Dagley
Laura Francesca Dagley
MFMomeneh Foroutan
Momeneh Foroutan
TMTimothy R. McCulloch
Timothy R. McCulloch
Nicholas D HuntingtonNicholas D Huntington
Nicholas D Huntington
Antibodies targeting “immune checkpoints” have revolutionized cancer therapy by reactivating tumor-resident cytotoxic lymphocytes, primarily CD8+ T cells. Interest in targeting analogous pathways in other cytotoxic lymphocytes is growing. Natural killer (NK) cells are key to cancer immunosurveillance by eradicating metastases and driving solid tumor inflammation. NK-cell antitumor function is dependent on the cytokine IL15. Ablation of the IL15 signaling inhibitor CIS (Cish) enhances NK-cell antitumor immunity by increasing NK-cell metabolism and persistence within the tumor microenvironment (TME). The TME has also been shown to impair NK-cell fitness via the production of immunosuppressive transforming growth factor β (TGFβ), a suppression which occurs even in the presence of high IL15 signaling. Here, we identified an unexpected interaction between CIS and the TGFβ signaling pathway in NK cells. Independently, Cish- and Tgfbr2-deficient NK cells are both hyperresponsive to IL15 and hyporesponsive to TGFβ, with dramatically enhanced antitumor immunity. Remarkably, when both these immunosuppressive genes are simultaneously deleted in NK cells, mice are largely resistant to tumor development, suggesting that combining suppression of these two pathways might represent a novel therapeutic strategy to enhance innate anticancer immunity.

1 January 2019 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
ANAlexsandro V. Nogueira
Alexsandro V. Nogueira
GRGustavo R. Rossi
Gustavo R. Rossi
MIMarcello Iacomini
Marcello Iacomini
GSGuilherme Lanzi Sassaki
Guilherme Lanzi Sassaki
ETEdvaldo S. Trindade
Edvaldo S. Trindade
TCThales R. Cipriani
Thales R. Cipriani

1 December 2017 in Carbohydrate Polymers
Verified
Journal Article
Closed access
SBS.M.P. Biscaia
S.M.P. Biscaia
ECE.R. Carbonero
E.R. Carbonero
DBD.L. Bellan
D.L. Bellan
BBB.S. Borges
B.S. Borges
CCC.R. Costa
C.R. Costa
ETEdvaldo Trindade
Edvaldo Trindade

4 November 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
NONatacha Omer
Natacha Omer
WNWayne Nicholls
Wayne Nicholls
BRBronte Ruegg
Bronte Ruegg
FSFernando Souza-Fonseca-Guimaraes
Fernando Souza-Fonseca-Guimaraes
GRGustavo Rodrigues Rossi
Gustavo Rodrigues Rossi
Osteosarcoma, Ewing sarcoma (EWS), and rhabdomyosarcoma (RMS) are the most common pediatric sarcomas. Conventional therapy for these sarcomas comprises neoadjuvant and adjuvant chemotherapy, surgical resection of the primary tumor and/or radiation therapy. Patients with metastatic, relapsed, or refractory tumors have a dismal prognosis due to resistance to these conventional therapies. Therefore, innovative therapeutic interventions, such as immunotherapy, are urgently needed. Recently, cancer research has focused attention on natural killer (NK) cells due their innate ability to recognize and kill tumor cells. Osteosarcoma, EWS and RMS, are known to be sensitive to NK cell cytotoxicity in vitro. In the clinical setting however, NK cell cytotoxicity against sarcoma cells has been mainly studied in the context of allogeneic stem cell transplantation, where a rapid immune reconstitution of NK cells plays a key role in the control of the disease, known as graft-versus-tumor effect. In this review, we discuss the evidence for the current and future strategies to enhance the NK cell-versus-pediatric sarcoma effect, with a clinical focus. The different approaches encompass enhancing antibody-dependent NK cell cytotoxicity, counteracting the NK cell mechanisms of self-tolerance, and developing adoptive NK cell therapy including chimeric antigen receptor-expressing NK cells.